Overview of preoperative radiochemotherapy in breast cancer: Past or future?

Clinical and Translational Oncology

Volumn 13, Issue 7, 2011, Pages 446-450

  Bourgier, Céline ^a   Calvo, Felipe A ^b   Marsiglia, Hugo ^a,c   Martín, Miguel ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Instituto Madrileno de Oncologia   (Spain)

Author keywords

Breast cancer; Chemo radiation; Neoadyuvant; Preoperative; Radiochemotherapy

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; PREDNISONE; RADIOSENSITIZING AGENT; TRASTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; INFLAMMATORY BREAST CANCER; IONIZING RADIATION; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; RADIOSENSITIZATION; TREATMENT INDICATION; BRACHYTHERAPY; BREAST TUMOR; CLINICAL TRIAL (TOPIC); FEMALE; MULTIMODALITY CANCER THERAPY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; PREOPERATIVE CARE;

EID: 82255162091     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0681-2     Document Type: Article

References (66)

1. Davila E, Vogel CL (1984) Management of locally advanced breast cancer (stage III): a review. Int Adv Surg Oncol 7:297-327
2. Hortobagyi GN (1990) Comprehensive management of locally advanced breast cancer. Cancer 66:1387-1391 (Pubitemid 20307955)
3. Zucali R, Uslenghi C, Kenda R et al (1976) Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer 37:1422-1431
4. van der Hage JA, van de Velde CJ, Julien JP et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237
5. Harris EE, Schultz D, Bertsch H et al (2003) Tenyear outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 55:1200-1208 (Pubitemid 36338285)
6. Bertucci F, Tarpin C, Charafe-Jauffret E et al (2004) Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment. Bone Marrow Transplant 33:913-920 (Pubitemid 38660124)
7. Viens P, Palangie T, Janvier M et al (1999) Firstline high-dose sequential chemotherapy with rGCSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 81:449-456 (Pubitemid 29458798)
8. Veyret C, Levy C, Chollet P et al (2006) Inflammatory breast cancer outcome with epirubicinbased induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 107:2535-2544 (Pubitemid 44845605)
9. Damast S, Ho AY, Montgomery L et al (2010) Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. Int J Radiat Oncol Biol Phys 77:1105-1112
10. Hortobagyi GN, Ames FC, Buzdar AU et al (1988) Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507-2516 (Pubitemid 19006431)
11. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188-194 (Pubitemid 40277368)
12. Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785 (Pubitemid 351264391)
13. Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 96-102
14. Lingos TI, Recht A, Vicini F et al (1991) Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 21:355-360
15. Zambetti M, Moliterni A, Materazzo C et al (2001) Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19:37-43 (Pubitemid 32063477)
16. Bollet MA, Sigal-Zafrani B, Gambotti L et al (2006) Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study. Eur J Cancer 42:2286-2295 (Pubitemid 44307620)
17. Chakravarthy AB, Kelley MC, McLaren B et al (2006) Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res 12:1570-1576
18. Formenti SC, Volm M, Skinner KA et al (2003) Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 21:864-870 (Pubitemid 46606446)
19. Vaughn CB, Chapman J, Chen SS et al (1988) Locally advanced adenocarcinoma of the breast without distant metastasis treated with multimodal therapies. Cancer Invest 6:467-474 (Pubitemid 19042658)
20. Ueno NT, Buzdar AU, Singletary SE et al (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40:321-329 (Pubitemid 27276136)
21. Huang E, McNeese MD, Strom EA et al (2002) Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys 53:1225-1233 (Pubitemid 34787859)
22. Gaui MF, Amorim G, Arcuri RA et al (2007) A phase II study of second-line neoadjuvant chemotherapy with capecitabine and radiation therapy for anthracycline-resistant locally advanced breast cancer. Am J Clin Oncol 30:78-81 (Pubitemid 46213829)
23. Ghorbel I, Heymann S, Delaloge S et al (2010) Effect of preoperative concomitant chemoradiotherapy in chemotherapy-refractory breast cancer on feasibility of curative surgery and pathologic tumor response. J Clin Oncol 28:7s
24. Chargari C, Kirova YM, Cottu P et al (2009) Progressive inflammatory breast cancer in patient receiving chemotherapy: the importance of radiotherapy as a part of locoregional treatment. Radiother Oncol 90:160-161
25. Mauriac L, MacGrogan G, Avril A et al (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47-52 (Pubitemid 29090591)
26. Broet P, Scholl SM, de la Rochefordiere A et al (1999) Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat 58:151-156 (Pubitemid 30032487)
27. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469 (Pubitemid 29075229)
28. Bonadonna G, Valagussa P, Brambilla C et al (1998) Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100 (Pubitemid 28041584)
29. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685 (Pubitemid 28363030)
30. Jones RL, Lakhani SR, Ring AE et al (2006) Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 94:358-362 (Pubitemid 43237560)
31. Thoms WW Jr, McNeese MD, Fletcher GH et al (1989) Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 17:739-745 (Pubitemid 19250526)
32. Bristol IJ, Woodward WA, Strom EA et al (2008) Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 72:474-484
33. Mourali N, Tabbane F, Muenz LR et al (1993) Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest 11:363-370 (Pubitemid 23225910)
34. Pessoa E, Dunant A, Heymann S et al (2010) Twenty-year results of alternating radiotherapy and chemotherapy in nonmetastatic inflammatory breast cancer. J Clin Oncol 28:638
35. Rouesse J, Friedman S, Sarrazin D et al (1986) Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 4: 1765-1771 (Pubitemid 17226665)
36. Buzdar AU, Singletary SE, Theriault RL et al (1999) Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 17:3412-3417 (Pubitemid 29517908)
37. Swain SM, Sorace RA, Bagley CS et al (1987) Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889-3894 (Pubitemid 17105745)
38. Karlsson YA, Malmstrom PO, Hatschek T et al (1998) Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications. Cancer 83:936-947 (Pubitemid 28401928)
39. Formenti SC, Symmans WF, Volm M et al (1999) Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 9:34-42 (Pubitemid 29190409)
40. Jordan MA, Thrower D, Wilson L (1991) Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51:2212-2222
41. Wilson L, Panda D, Jordan MA (1999) Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct Funct 24:329-335
42. Edelstein MP, Wolfe LA 3rd, Duch DS (1996) Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23:41-47 (Pubitemid 26130114)
43. Gridelli C, Guida C, Barletta E et al (2000) Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. Lung Cancer 29:131-137 (Pubitemid 30645822)
44. Geh JI (2002) The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 38:300-313 (Pubitemid 34137004)
45. Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACHNC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955 (Pubitemid 30148259)
46. Rose PG (2002) Chemoradiotherapy for cervical cancer. Eur J Cancer 38:270-278 (Pubitemid 34137001)
47. Simoens C, Lardon F, Pauwels B et al (2008) Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer 8:65
48. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653-1664
49. Byfield JE, Calabro-Jones P, Klisak I et al (1982) Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 8:1923-1933 (Pubitemid 13167377)
50. Rich TA, Shepard RC, Mosley ST (2004) Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214-2232 (Pubitemid 41095158)
51. Bruso CE, Shewach DS, Lawrence TS (1990) Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 19:1411-1417
52. McGinn CJ, Shewach DS, Lawrence TS (1996) Radiosensitizing nucleosides. J Natl Cancer Inst 88:1193-1203 (Pubitemid 26302032)
53. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137 (Pubitemid 33674041)
54. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374 (Pubitemid 39100473)
55. Harari PM, Huang SM (2001) Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289 (Pubitemid 32959663)
56. Bianco C, Tortora G, Bianco R et al (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3250-3258 (Pubitemid 35155038)
57. She Y, Lee F, Chen J et al (2003) The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 9:3773-3778 (Pubitemid 37169247)
58. Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378
59. Pietras RJ, Poen JC, Gallardo D et al (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-1355 (Pubitemid 29136268)
60. Liang K, Lu Y, Jin W et al (2003) Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2:1113-1120
61. Horton JK, Halle J, Ferraro M et al (2010) Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys 76:998-1004
62. Sambade MJ, Camp JT, Kimple RJ et al (2009) Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol 93:639-644
63. Sambade MJ, Kimple RJ, Camp JT et al (2010) Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/ EGFR+ breast tumor xenografts. Int J Radiat Oncol Biol Phys 77:575-581
64. Zhou H, Kim YS, Peletier A et al (2004) Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR-and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 58:344-352 (Pubitemid 38142458)
65. Sofia Vala I, Martins LR, Imaizumi N et al (2010) Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One 5:e11222
66. Goyal S, Rao MS, Khan A et al (2011) Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab. Int J Radiat Oncol Biol Phys 79:408-413